Video

REVIEW UroToday

Practice Guidelines Reviews - AUA 2023 Prostate

Search

Reviewing Evidence on Bone Health and Future Directions in Updated Prostate Cancer Guidelines, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on bone health and future directions. They emphasize the importance of bone health, particularly for men with advanced prostate cancer who are at increased risk of bone complications due to age, ADT treatment, and bone metastases. The guidelines recommend assessing the risk of fragility fractu...
Guideline Revisions Seek to Optimize Detection and Management of Recurrent Prostate Cancer Without Evident Metastasis, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines on advanced prostate cancer, focusing on biochemically recurrent prostate cancer without metastasis after local treatment. The guidelines emphasize informing patients about the risk of developing metastatic disease and recommend serial PSA measurements and clinical evaluations. High-risk patients, identified by pathologic grade or...
Epidemiological Trends and Treatment Innovations in Advanced Prostate Cancer: An In-Depth Analysis of the AUA's Amended 2023 Guidelines, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen review the 2023 amended AUA guidelines on advanced prostate cancer. They focus on the epidemiology, early evaluation, and patient counseling. The guidelines, led by Dr. Michael Cookson, form part of a comprehensive six-part series. The discussion highlights the importance of understanding evidence strength, ranging from high-quality randomized trials (Grade A) to st...
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the updated AUA guidelines for advanced prostate cancer, focusing on metastatic castration-resistant prostate cancer (mCRPC). The guidelines emphasize the importance of baseline labs, metastatic disease location, and symptoms for prognosis and treatment decisions in mCRPC patients. Statement #25 highlights the significance of various lab markers and metastat...
AUA Guidelines Provide Roadmap for Assessing Disease Burden and Personalizing Systemic Therapies in Metastatic Hormone Sensitive Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2023 amended AUA guidelines for advanced prostate cancer, focusing on metastatic hormone-sensitive prostate cancer (mHSPC). They emphasize the importance of assessing metastatic disease extent in newly diagnosed mHSPC patients, as it significantly influences systemic therapy choices. The guidelines recommend using either conventional imaging or PSMA PET...